Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties.
- Compass expects to complete its rolling NDA submission within two weeks, supported by two Phase III studies and a Phase IIb study that together enrolled more than 1,000 patients.
- The National Priority Voucher sets a one-to-two-month FDA review target, but the company described approval as a possibility, not a certainty.
- Compass reported $444 million in cash as of September 30 and said it expects funds to carry it through launch and into 2028.
- Commercial preparations continue: non-field commercial roles are filled, hiring for the field force is underway, and payer and clinician engagement is ongoing.
- The registrationally designed PTSD trial is actively enrolling; Compass cited PTSD as a potential label expansion opportunity alongside its TRD launch focus.
Community Discussion